Drug Trial Radar · NCT04647487
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
Last checked: Nov 20, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Apr 21, 2021
Primary completion
Nov 11, 2022
Study completion Nov 11, 2022
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Dec 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
Conditions
- Breast Cancer
Interventions
LY3484356Drug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Estrogen Receptor (ER) ExpressionTime frame: Baseline, Day 15
Locations
19 sites in 6 countries. Site status is shown where the registry gives one.
Winship Cancer Center Emory University
Atlanta, Georgia
Northwestern Memorial Hosptial
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Sarah Cannon Research Institute SCRI
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
University of Vermont Medical Center
Burlington, Vermont
Institut Jules Bordet
Brussel - Capital, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium
Hôpital René Huguenin
Saint-Cloud, Hauts-de-Seine, France
Klinikum der Universitaet Muenchen
München, Germany
Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany
Helios Kliniken Schwerin
Schwerin, Mecklenburg-Vorpommern, Germany
Hospital Clinic I Provincial
Barcelona, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Hospital Madrid Norte Sanchinarro
Madrid, Spain
The Royal Cornwall Hospital
Truro, Cornwall, United Kingdom
Barts Cancer Institute
London, London City, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.